

## DURECT Corporation Invites You to Join its Third Quarter 2013 Earnings Conference Call

CUPERTINO, Calif., Oct. 28, 2013 /PRNewswire/ — In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2013 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet onMonday, November 4, 2013 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at <a href="http://www.www.durect.com">http://www.www.durect.com</a> and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

## **About DURECT Corporation**

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY<sup>®</sup>, POSIDUR<sup>™</sup>, ELADUR<sup>®</sup>, and TRANSDUR<sup>®</sup>-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.www.durect.com.

NOTE: POSIDUR<sup>™</sup>, SABER<sup>®</sup>, ORADUR<sup>®</sup>, TRANSDUR<sup>®</sup>, and ELADUR<sup>®</sup> are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

**SOURCE DURECT Corporation** 

Matthew J. Hogan, Chief Financial Officer, 408-777-4936